brucellosis
Conditions
Interventions
Acute phase - doxycycline (0.1g bid po) + rifampicin (10mg/kg qd) for 6 weeks:None
Acute phase - doxycycline (0.1g bid po) + rifampicin (10mg/kg qd) for 12 weeks:None
Chronic phase(complicated with osteoarthropathy) - doxycycline (0.1g bid po) + rifampicin (10mg/kg qd) + ciprofloxacin (750mg bid) for 18 weeks:None
Chronic phase(complicated with osteoarthropathy) - doxycycline (0.1g bid po) + rifampicin (10mg/kg qd) + ciprofloxacin (750mg bid) for 24weeks:None
Sponsors
The First Affiliated Hospital of Xinjiang Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: ? To join the group voluntarily, able to understand and sign informed consent; ? According to the People's Republic of China health industry standards issued "brucellosis diagnosis" confirmed cases: acute, chronic (complicated with osteoarthrosis) brucellosis patients; (3) Willing and suitable to receive any of the following treatment options: Acute phase: Regimen 1: Doxycycline (0.1g bid po) + rifampicin (10mg/kg qd) for 6 weeks; Regimen 2: Doxycycline (0.1g bid po) + rifampicin (10mg/kg qd) for 12 weeks Chronic phase (complicated with osteoarthropathy) : Regimen 1: Doxycycline (0.1g bid po) + rifampicin (10mg/kg qd) + ciprofloxacin (750mg bid) for 18 weeks; Regimen 2: Doxycycline (0.1g bid po) + rifampicin (10mg/kg qd) + ciprofloxacin (750mg bid) for 24 weeks;
Exclusion criteria
Exclusion criteria: ?A combination of other systemic diseases (including uncontrolled diabetes mellitus; Unstable coronary heart disease; Diseases of liver and kidney insufficiency; Malignant tumor; Ischemic/hemorrhagic stroke; Moderate to severe anemia; Parkinson's synthesis, etc.); ? Brucellosis patients with orchitis, meningitis, endocarditis, vasculitis and other complications; ? Mental illness with poor activity control, including delusions, hallucinations or suicidal ideation; ? Pregnant and lactating women; ? History of alcoholism, drug addiction or drug allergy;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Brucellosis titer;blood culture;Patient's clinical symptoms; | — |
Secondary
| Measure | Time frame |
|---|---|
| skin reaction factor;blood routine examination;complication;Biochemical blood;erythrocyte sedimentation rate (ESR); | — |
Countries
China
Contacts
Public ContactLuXiaobo
The First Affiliated Hospital of Xinjiang Medical University
Outcome results
None listed